The oncology reimbursement landscape continues to present ever-evolving challenges for clinicians and others that work with patients with cancer. As a response to these ongoing challenges, help is available through the NCCN Virtual Reimbursement Resource Room.
Select a cancer or supportive care indication or select a reimbursement program below to learn about reimbursement help and services available to you to help your practice mitigate reimbursement challenges.
Download the NCCN Reimbursement Resource App for Smartphones and Tablets
Download the NCCN Virtual Reimbursement Resource Room Guide
Now available for Apple and Android
smartphones and tablets! As a response to these ongoing challenges, help is available through the NCCN Reimbursement Resource App; users are able
to search for available resources and payment
Information on resources available are listed under three different tabs entitled: Search by Cancer Type or Supportive Care Indication, Search by Drug Name (brand or generic), and Search by Reimbursement or Assistance Program.
A printer-friendly 23 page resource to empower patients with cancer and their caregivers as you help them navigate the challenging reimbursement landscape.
Acute Promyelocytic Leukemia (APL)
AIDS Related Kaposi's Sarcoma
Anaplastic Large Cell Carcinoma
Basal Cell Carcinoma
Castrate Resistant Prostate Cancer
Chemotherapy-Induced Nausea and Vomiting (CINV)
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia (CML)
Gastroesophageal Junction Cancer
Gastrointestinal Stromal Tumor (GIST)
Mantle Cell Lymphoma
Metastatic Breast Cancer
Metastatic Colorectal Cancer
Multicentric Castleman's Disease
Mycosis Fungoides/Sezary Syndrome
Neuroendocrine Tumors of Pancreatic Origin
Non-Small Cell Lung Cancer
Peripheral T-Cell Lymphoma
Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia
Prevention and Treatment of Cancer-Related Infections
Renal Cell Carcinoma
Soft Tissue Sarcoma
Abiraterone acetate (ZYTIGA®) --- Janssen CarePath
Ado-trastuzumab emtansine (Kadcyla) --- Genentech Access Solutions
Afatinib (GILOTRIF®) --- Boehringer Ingelheim Solutions Plus™
Arsenic Trioxide (Trisenox®) --- Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise)
bortezomib (Velcade®) --- Takeda Oncology- Velcade Reimbursement Assistance Program (VRAP)
Azacitidine for injection (Vidaza®) --- Celgene Patient Support®
Bendamustine (Treanda®) --- Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise)
Bevacizumab (Avastin®) --- Genentech Access Solutions
Capecitabine (Xeloda®) --- Genentech Access Solutions
Daratumumab (DARZALEX®) --- Janssen CarePath
Doxorubicin HCl liposome injection (DOXIL®) --- Janssen CarePath
Enzalutamide capsules (XTANDI) --- XTANDI Support SolutionsSM
Epoetin alfa (PROCRIT®) --- Janssen CarePath
Eribulin mesylate (HALAVEN®) --- Eisai Assistance Program (EAP)
Erlotinib (Tarceva) --- Genentech Access Solutions
Everolimus (Afinitor®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
filgrastim-sndz (ZARXIO®) --- Sandoz One Source™
Ibrutinib (IMBRUVICA®) --- YOU&i™ Support Program
Imatinib (Gleevec®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
ixazomib (NINLARO®) --- Takeda Oncology- NINLARO 1Point™
Lenalidomide (Revlimid®) --- Celgene Patient Support®
Letrozole (Femara®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
Nilotinib (Tasigna®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
Omacetaxine Mepesuccinate (Synribo®) --- Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise)
ONIVYDE® (irinotecan liposome injection) --- PROVYDE® (ONIVYDE Access Services)
Paclitaxel protein-bound particles for injectable suspension (albumin-bound) (Abraxane®) --- Celgene Patient Support®
Pemetrexed for injection (Alimta®) --- Lilly PatientOne: Reimbursement & Patient Assistance Programs
Pertuzumab (Perjeta) --- Genentech Access Solutions
Pomalidomide (Pomalyst®) --- Celgene Patient Support®
PROSIGNA® (PROSIGNA®) --- The Prosigna Patient Support Program (NanoString Technologies)
Ramucirumab (Cyramza®) --- Lilly PatientOne: Reimbursement and Patient Assistance Programs
Rituximab (Rituxan) --- Genentech Access Solutions
Rolapitant (VARUBI®) --- TOGETHER with TESARO™
Romidepsin for injection (Istodax®) --- Celgene Patient Support®
Ruxolitinib (tablets) (Jakafi®) --- IncyteCARES (Incyte Corporation)
Siltuximab (SYLVANT®) --- Janssen CarePath
Tbo-filgrastim (Granix™) --- Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise)
Thalidomide (Thalomid®) --- Celgene Patient Support®
TheraSphere® (TheraSphere®) --- BTG International Inc.: Reimbursement Services
Trabectedin (YONDELIS®) --- Janssen CarePath
Trastuzumab (Herceptin®) --- Genentech Access Solutions
(trifluridine and tipiracil) tablets (Lonsurf®) --- Taiho Oncology Patient Support
Vemurafenib (Zelboraf) --- Genentech Access Solutions
Vismodegib (Erivedge®) --- Genentech Access Solutions
Zoledronic acid (Zometa®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
- Your Patients - Your Practice - Your Choice
XTANDI Support Solutions℠ is designed as a single point of contact to help patients and their loved ones understand their coverage and reimbursement options for XTANDI (enzalutamide) capsules. Astellas is firmly committed to ensuring our patients have access to XTANDI, regardless of their financial status. We are here to answer questions about your insurance coverage and options for filling your prescription in order to get you started on therapy as quickly as possible.
Flexible and integrated resources for patient access and support:
XTANDI Patient Savings Program℠
Quick Start+℠ for XTANDI
To enable rapid initiation of treatment, the Quick Start+™ program for XTANDI provides a one-time, 14-day gratis fill supply of XTANDI that requires a physician prescription. Quick Start+ is intended for new patients who have not received a coverage decision from their payer (for example, a benefit verification or prior authorization is pending) in time to start therapy in 10 business days. Quick Start+™ offers several benefits:
Astellas Access Program℠
Astellas is committed to supporting and maintaining access to medications for patients who are treated with an Astellas product.
The Astellas Access Program℠ for XTANDI is designed for patients who have no health insurance. This program provides free XTANDI to patients who qualify for enrollment based on insurance and household income status. Eligibility is determined on a patient-specific basis. XTANDI Support Solutions℠ can quickly determine whether a patient is eligible for enrollment.
If you need assistance with the Astellas eService site, XTANDI Support Solutions℠ or have any questions on coding, coverage, and reimbursement for Astellas products, please contact us between the hours of 9:00 AM and 8:00 PM ET Monday through Friday.
XTANDI Support Solutions℠
Monday – Friday, 9:00 AM – 8:00 PM ET
Phone: 1.855.8XTANDI (1.855.898.2634)
Astellas Access Services℠
P.O. Box 13185
La Jolla, CA 92039
For Full Prescribing Information please see www.Astellas.com or contact Astellas Medical Communication at 1.800.961.0018.
XTANDI and Astellas are trademarks of Astellas Pharma Inc.
XTANDI Support Solutions℠ is a component of Astellas Access Services℠.
Making patient support our priority by providing a broad range of access, reimbursement and clinical support solutions for patients who are prescribed GILOTRIF® (afatinib) tablets
Call Solutions Plus at 1-877-814-3915 from 8AM to 8PM EST or online at www.bisolutionsplus.com
BTG is a specialist healthcare company focused on three business areas: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
BTG's Interventional Medicines include Interventional Oncology products used to treat patients with liver tumors and Interventional Vascular products used to treat patients with severe blood clots and patients with varicose veins in the great saphenous vein system of the leg.
BTG's Specialty Pharmaceutical products include antidotes to treat snake envenomation and toxicity associated with medicines used for heart conditions and cancer.
Company and product website addresses:
A single source for access support
Celgene Patient Support® provides patients support with accessing their prescribed Celgene oncology medications. No matter what type of insurance patients have, a Celgene Patient Support® Specialist is here to help. Patients will speak to the same Specialist every time they call. A Specialist can provide a range of services when one of our medications is prescribed.
*Patients must meet specified financial and insurance eligibility criteria to qualify for assistance.
There are 4 simple ways to enroll your patient in Celgene Patient Support®:
Eisai's commitment to innovative solutions in disease prevention, treatment and care for the health and
well-being of people worldwide is embodied in our human health care (hhc) mission: we give first
thoughts to patients and their families by helping to facilitate access to necessary medicines.
With this in mind, the Eisai Assistance Program (EAP) provides dedicated reimbursement and access
support for patients and healthcare professionals to reduce barriers to patient access to medicines.
Specifically, EAP offers the following services:
To learn more about the Eisai Assistance Program, please visit our website or call our toll‐free number.
Phone: 1.866.61.EISAI (1.866.613.4724)
(Monday-Friday, 8 AM to 8 PM, ET)
We Focus on Access So You Can Focus on Health
If you are concerned about paying for your Genentech medicine, we are here to help. Whether you have health care coverage or not, we can help you by:
Visit Genentech-Access.com to learn more about these programs and how to get started. To speak live with one of our Specialists, call (866) 4ACCESS/(866) 422-2377.
Genoptix collaborates with healthcare providers on complex oncology cases to provide definitive diagnoses to help improve patient outcomes. We partner with most major insurance companies, as well as Medicare. If Genoptix is not contracted with an insurance carrier, we will consult with the healthcare or insurance provider to determine a course of action.
Results from a regional retrospective study show economic benefits associated with the COMPASS hematopathologist-directed, centralized diagnostic workflow. Genoptix patients demonstrated improved transfusion independence and fewer office visits, lab tests, diagnoses, and transfusions, saving considerable time and resources. Source: Engel-Nitz NM, et al.
For any reimbursement questions, call Genoptix at 800-755-0802 or visit Genoptix.com
IncyteCARES (Connecting to Access, Reimbursement, Education and Support) was established by Incyte to assist providers, patients, and caregivers through a single point of contact with reimbursement assistance, patient access, and distribution coordination for Jakafi® (ruxolitinib).
IncyteCARES assists healthcare professionals and eligible patients with product access through a suite of services, including:
You can contact IncyteCARES, between 8 AM – 8 PM ET, by calling 1-855-4-JAKAFI (855-452-5234) or visit www.IncyteCARES.com for more information.
Janssen CarePath is your one source for resources focused on access, affordability, and treatment support for your patients. You, your staff, and your patients have the flexibility to choose which support and resources you may want to use. We can help make it easier for you and your patients to get the resources you both may need.
Access support to help your patients start on treatment you prescribe
Janssen CarePath helps verify insurance coverage for your patients and provides reimbursement information.
Our offerings include:
Affordability support to help your patients start and stay on treatment you prescribe
Janssen CarePath can help you find out what affordability assistance may be available for your patients taking Janssen medicines:
Treatment support to help your patients get informed and stay on prescribed treatment
Janssen CarePath helps keep your patients informed about their condition and the importance of staying on treatment with:
Click here for more information about how to enroll your patients in Janssen CarePath or call your personally assigned Janssen CarePath Care Coordinator.
Contact: Janssen CarePath
Monday-Friday, 8:00 AM - 8:00 PM ET
The Lilly PatientOne program is committed to helping eligible patients access support programs for Lilly Oncology products they are prescribed. It aims to address both financial and coverage issues for qualified uninsured, underinsured, and insured patients who are prescribed a Lilly Oncology product. PatientOne strives to offer resources, ranging from benefits investigations to financial assistance and appeals information, that provide reliable and individualized treatment support for eligible patients.
Services offered by this program include:
Patient Assistance Program
Reimbursement assistance for eligible Lilly Oncology products for an approved diagnosis
Denied claim appeals
For more information call 1-866-4PatOne (1-866-472-8663) Monday–Friday, 9AM–7PM ET or visit
Patient Access Network (PAN) Foundation (866.316.7263)
The Patient Access Network Foundation is an independent, nationwide 501(c)(3) organization dedicated to providing help and hope to underinsured patients who are unable to afford the out-of-pocket expenses for their prescribed medications. Since 2004, PAN has provided over $1 billion in financial assistance to more than 500,000 people living with chronic or critical illnesses, across nearly 60 disease-specific programs. For applications and eligibility questions, call 866-316-PANF (7263). To learn more, visit www.PANFoundation.org.
Helping to make access to the therapies you need easier
Novartis Oncology is committed to helping patients living with cancer receive the medicines they need. Patient Assistance NOW Oncology offers quick and easy access to information about the broad array of support and reimbursement programs available.
You can get information about our Patient Assistance NOW Oncology support programs in 2 ways:
NanoString Technologies is committed to providing advanced actionable diagnostic and prognostic technology, helping improve cancer care for patients.
The Prosigna Patient Support Program is designed to help breast cancer patients gain access to the important information which can be obtained from the Prosigna Prognostic Breast Cancer Gene Signature. The program includes an array of services to meet the needs of patients and health care providers.
See Package Insert for further details at www.prosigna.com.
For additional information on The Prosigna Patient Support Program visit www.prosigna.com/patient-support or call 855-4-PROSIGNA (855-477-6744)
PROVYDE® (ONIVYDE Access Services) offers an array of services to help healthcare providers and their patients access ONIVYDE® (irinotecan liposome injection).
PROVYDE® can help by offering:
PROVYDE® (ONIVYDE Access Services)
Monday – Friday, 8AM – 5PM ET
Phone: 1.844.ONIVYDE (1.844.664.8933)
*Patients must meet specified financial and insurance eligibility criteria to qualify for assistance. Merrimack reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
†Functionally uninsured patients are those who may be enrolled in a health plan but do not have coverage for ONIVYDE.
Sandoz One Source™: Patient Support Services
Sandoz One Source is a comprehensive program designed to help simplify and support patient access. Sandoz One Source offers a variety of customized services for patients prescribed filgrastim-sndz (ZARXIO®) including:
Phone: 1.844.726.3691 (1.844.SANDOZ1) - Monday – Friday, 9:00 AM – 8:00 PM ET
P.O. Box 220188Charlotte, NC 28222-0188
* Maximum benefit of $10,000 annually. Prescription must be for an approved indication. This program is not health insurance. This program is for insured patients only; cash-paying or uninsured patients are not eligible. Patients are not eligible if prescriptions are paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TriCare, or private indemnity, or HMO insurance plans that reimburse the patient for the entire cost of their prescription drugs, or where prohibited by law. Patients can participate for a maximum of 12 months up to age 65. Co-Pay Program may not be combined with any other rebate, coupon, or offer. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.
ZARXIO and Sandoz One Source are trademarks Novartis AG.
©2016 Sandoz Inc., a Novartis company, 100 College Road West, Princeton, NJ 08540 All Rights Reserved S-ZRX-1329695 03/2016
Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise) offers reimbursement support for branded Teva Oncology products. Some of the options include benefit verification, prior authorization support and customer service through the claims and appeals process. CORE also provides referrals to the Teva Cares patient assistance program.
For more information or an introductory consult please call 1-888-587-3263 or visit www.TevaCore.com
We know getting patients access to LONSURF® (trifluridine and tipiracil) is a critical step in their treatment. We strive to make this process as simple as possible.
Access and reimbursement support
Specialty pharmacy (SP) prescription coordination
Alternate funding support
Personalized nurse support for treatment plan adherence upon request
We will quickly investigate each patient's LONSURF coverage, and help them get access to the LONSURF treatment they have been prescribed.
Call 1-844-TAIHO-4U (1-844-824-4648) or for more information visit www.TaihoPatientSupport.com
NINLARO 1Point is designed to assist patients with coverage, access, and staying on therapy
NINLARO 1Point is a comprehensive support program that offers an array of access and coverage services for NINLARO® (ixazomib) patients and their healthcare providers.
Our dedicated case management team can deliver personalized services that help NINLARO patients and providers navigate coverage requirements for NINLARO, streamline product access, and connect to helpful resources.
Contact us by phone
To get more information on access, coverage, and available support and services, call a NINLARO 1Point case manager.
Contact us by fax
To submit a request for insurance benefit verification, RapidStart enrollment, prescriptions for specialty pharmacy, or Patient Assistance Program enrollment.
Reimbursement services and more for your office and your patients
VRAP provides you and your patients with a full suite of services and resources designed to make access to therapy as easy as possible.
For your office: Filing claims
Our dedicated case managers help you and your practice get started
For your office: Managing claims
A dedicated case manager helps your office manage claims
For your patient: Treatment and Personal Support
Our dedicated case managers help assist your patients
For questions regarding the Takeda Oncology- Velcade Reimbursement Assistance Program (VRAP), please call (866) 835-2233, option 2.
TOGETHER with TESARO™ is a patient resource program dedicated to supporting people bravely fighting cancer. The program offers solutions for medication access and affordability throughout each patient's journey. TESARO's expert case management team facilitates a seamless process to ensure TESARO patients get the individualized support needed.
For more information about TOGETHER with TESARO, call 1-844-2TESARO (1-844-283-7276), or visit www.TOGETHERwithTESARO.com
Personalized assistance for IMBRUVICA® (ibrutinib) patients to help them:
We can help patients learn about access to IMBRUVICA® through:
Regardless of insurance type, we can help your patients understand their options
Nurse Call Support & Resources
Your patients can talk to YOU&i™ nurses who can answer questions and provide information about IMBRUVICA® and their disease
Enrolling in the YOU&i™ Support Program is easy
Contact YOU&i™ Support
Monday – Friday, 8:00 AM – 8:00 PM ET
Before prescribing IMBRUVICA® (ibrutinib), please see the full Prescribing Information available at www.IMBRUVICA.com.
Industry: Provide needed information on reimbursement programs and service available
For information on participating in the NCCN Reimbursement Resource Room or other support opportunities, please contact Jennifer Tredwell at 215.690.0274 or email@example.com.
NCCN Member Institutions|
275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280Copyright © 2017 National Comprehensive Cancer Network, All Rights Reserved